2,6-二甲基-3-硝基-4(1H)-吡啶酮 | 13603-45-7

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2,6-二甲基-3-硝基-4(1H)-吡啶酮
• 中文别名: 2,6-二甲基-4-羟基-3-硝基吡啶
• 英文名称: 2,6-dimethyl-4-hydroxy-3-nitropyridine
• 英文别名: 2,6-dimethyl-3-nitro-4-pyridinol；2,6-dimethyl-3-nitropyridin-4-ol；2,6-dimethyl-3-nitro-pyridin-4-ol；2,6-Dimethyl-3-nitro-4-hydroxy-pyridin；3-Nitro-2,6-dimethyl-4-pyridinol；4-Hydroxy-3-nitro-2,6-lutidin；2,6-dimethyl-3-nitro-1H-pyridin-4-one
• CAS: 13603-45-7
• 化学式: C₇H₈N₂O₃
• mdl: MFCD18253578
• 分子量: 168.152
• InChiKey: PKAUZTQOCSCVLK-UHFFFAOYSA-N

物化性质

• 熔点：
  296 °C
• 沸点：
  363.7±37.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,6-Dimethyl-3-nitro-4-pyridinol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Dimethyl-3-nitro-4-pyridinol
CAS number: 13603-45-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8N2O3
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,6-二甲基-3-硝基-4(1H)-吡啶酮 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 以69%的产率得到4-氯-2,6-二甲基-3-硝基吡啶
  参考文献：
  名称：

  4-和6-取代的噻唑并[4,5- c ]吡啶的合成

  摘要：

  描述了一种4,6-取代的噻唑[4,5- c ]吡啶的一般合成方法，涉及一个新的一锅硫醇脱保护环化关键步骤。

  DOI：

  10.1016/j.tetlet.2010.03.070
• 作为产物：
  描述：

  2,6-二甲基-4-羟基吡啶 在 硫酸 、 硝酸 作用下， 生成 2,6-二甲基-3-硝基-4(1H)-吡啶酮
  参考文献：
  名称：

  4-和6-取代的噻唑并[4,5- c ]吡啶的合成

  摘要：

  描述了一种4,6-取代的噻唑[4,5- c ]吡啶的一般合成方法，涉及一个新的一锅硫醇脱保护环化关键步骤。

  DOI：

  10.1016/j.tetlet.2010.03.070

文献信息

• Platelet activating factor antagonists
  申请人：Pfizer Inc.

  公开号：US04935430A1

  公开（公告）日：1990-06-19

  Platelet activating factor antagonists of formula (I): ##STR1## wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, aryl (C.sub.1 -C.sub.4) alkoxy, fluoro (C.sub.1 -C.sub.4) alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring; R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C.sub.1 -C.sub.4 alkyl) piperazinyl or N-(C.sub.2 -C.sub.4 alkanoyl)-piperazinyl group; or R.sup.2 is H or C.sub.1 -C.sub.4 alkyl and R.sup.1 is CN, C.sub.3 -C.sub.7 cycloalkyl, aryl, heteroaryl or a C.sub.1 -C.sub.4 alkyl group substituted by one or more substituents selected from C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxycarbonyl, aryl or heteroaryl; Z is selected from C.sub.1 -C.sub.6 alkoxy, aryl (C.sub.1 -C.sub.4) alkoxy, hydroxy, and --NR.sup.4 R.sup.5 wherein each of R.sup.4 and R.sup.5 is independently H or C.sub.1 -C.sub.6 alkyl, or R.sup.4 and R.sup.5 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C.sub.1 -C.sub.4 alkyl) piperazinyl group; Y is 1,4 phenylene or pyridine-2,5-diyl, and X is a 5 or 6 membered aromatic heterocyclic group containing one or more nitrogen atoms in its ring; which ring may be fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, at least one of said heterocyclic rings optionally also containing an oxygen or sulphur atom, and being optionally substituted with one or more substituents selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3 and CN; and their pharmaceutically acceptable salts.

  公式（I）的血小板活化因子拮抗剂：其中R是苯基或苯基，其上取代基可从硝基，卤素，C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，芳基（C.sub.1-C.sub.4）烷氧基，氟基（C.sub.1-C.sub.4）烷氧基，C.sub.1-C.sub.4烷基硫基，C.sub.1-C.sub.4烷基磺酰基，羟基，三氟甲基和氰基中选择一个或多个取代基；或者是与二噁唑环融合的苯基；R.sup.1和R.sup.2分别独立地为H或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2一起形成吡咯啉基，哌啶基，吗啉基，哌嗪基，N-(C.sub.1-C.sub.4烷基)哌嗪基或N-(C.sub.2-C.sub.4烷酰基)-哌嗪基；或者R.sup.2为H或C.sub.1-C.sub.4烷基，R.sup.1为CN，C.sub.3-C.sub.7环烷基，芳基，杂环芳基或一个C.sub.1-C.sub.4烷基，其上取代基可从C.sub.3-C.sub.7环烷基，C.sub.1-C.sub.4烷氧羰基，芳基或杂环芳基中选择一个或多个取代基；Z从C.sub.1-C.sub.6烷氧基，芳基（C.sub.1-C.sub.4）烷氧基，羟基和--NR.sup.4R.sup.5中选择，其中R.sup.4和R.sup.5中的每一个独立地为H或C.sub.1-C.sub.6烷基，或者R.sup.4和R.sup.5一起形成吡咯啉基，哌啶基，吗啉基，哌嗪基或N-(C.sub.1-C.sub.4烷基)哌嗪基；Y为1,4-苯基或吡啶-2,5-二基，X为含有一个或多个氮原子的5或6成员芳香杂环基团；该环可能与苯环融合，或与进一步含有一个或多个氮原子的5-或6成员芳香杂环环融合，至少其中一个杂环环可选地还含有一个氧原子或硫原子，并可选地取代一个或多个取代基，所述取代基可从C.sub.1-C.sub.4烷基，C.sub.1-C.sub.4烷氧基，卤素，CF.sub.3和CN中选择；以及其药学上可接受的盐。
• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] ACTIVATEUR D'INHIBITEURS DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2014107277A1

  公开（公告）日：2014-07-10

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.

  这项发明涉及到按照式(I)的新化合物，这些化合物是Enhancer of Zeste Homolog 2 (EZH2)的抑制剂，以及包含它们的药物组合物，它们的制备方法，以及它们在治疗癌症中的应用。表观遗传修饰在调控许多细胞过程中起着重要作用，包括细胞增殖、分化和细胞存活。全局表观遗传修饰在癌症中很常见，包括DNA和/或组蛋白甲基化的全局变化，非编码RNA和核小体重塑的失调，导致致癌基因、抑癌基因和信号通路的异常激活或失活。
• 1,4-dihydropyridine derivatives
  申请人：Pfizer Inc.

  公开号：US04963560A1

  公开（公告）日：1990-10-16

  The invention provides compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is phenyl substituted by halo; R.sup.1 is C.sub.1 -C.sub.4 alkyl; is hydrogen, C.sub.5 -C.sub.7 cycloalkyl, benzyl or C.sub.1 -C.sub.4 alkyl, said C.sub.1 -C.sub.4 alkyl group being optionally substituted by cyano, trimethylsilyl or C.sub.1 -C.sub.3 alkoxy; and "Het" is ##STR2## wherein R.sup.3 is hydrogen or methyl. The compounds are useful in the treatment of allergic, inflammatory and hypersecretory conditions, and circulatory shock, stroke and thrombosis.

  该发明提供了以下结构的化合物及其药用盐，其中R为卤代苯基；R.sup.1为C.sub.1 -C.sub.4烷基；是氢、C.sub.5 -C.sub.7环烷基、苄基或C.sub.1 -C.sub.4烷基，所述C.sub.1 -C.sub.4烷基基团可以选择性地被氰基、三甲基硅基或C.sub.1 -C.sub.3烷氧基取代；"Het"为以下结构：其中R.sup.3为氢或甲基。这些化合物在治疗过敏、炎症和分泌过多症状以及循环休克、中风和血栓形成方面具有用途。
• Pyrido[3,4-e]-1,2,4-triazines and related heterocycles as potential antifungal agents
  作者：Marvin F. Reich、Paul F. Fabio、Ving J. Lee、Nydia A. Kuck、Ray T. Testa

  DOI：10.1021/jm00131a010

  日期：1989.11

  6-c]quinolines, and related fused triazines are described. Methyl, amino, and acylamino substituents were placed in the pyridyl ring of the former system. Other structural modifications included various alkyl, cycloalkyl, substituted phenyl, and heterocyclic groups in the 3-position of these ring systems. In agar dilution assays, actives in this series inhibited strains of Candida, Aspergillus, Mucor, and Trychophyton

  描述了一系列吡啶并[3,4-e] -1,2,4-三嗪，1,2,4-三嗪[5,6-c]喹啉和相关的稠合三嗪的制备和生物学活性。甲基，氨基和酰基氨基取代基置于前一系统的吡啶基环中。其他结构修饰包括在这些环系统的3位上的各种烷基，环烷基，取代的苯基和杂环基。在琼脂稀释测定中，该系列中的活性物质以MIC小于或等于16微克/ mL抑制念珠菌，曲霉，Mucor和Trychophyton菌种。
• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] INHIBITEURS DE L'AMPLIFICATEUR DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015004618A1

  公开（公告）日：2015-01-15

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  本发明涉及一种新型化合物，符合式（I），它们是增强子Zeste同源蛋白2（EZH2）的抑制剂，包含它们的药物组合物，其制备方法以及它们在治疗癌症中的用途。